Spyglass Pharma (NASDAQ:SGP) Rating Increased to Strong-Buy at Jefferies Financial Group

Spyglass Pharma (NASDAQ:SGP - Get Free Report) was upgraded by investment analysts at Jefferies Financial Group to a "strong-buy" rating in a note issued to investors on Tuesday, Marketbeat Ratings reports.Get Spyglass Pharma alerts:Several other equities research analysts also recently weighed in on SGP. Citigroup started coverage on shares of Spyglass Pharma in a report on Tuesday. They issued a "buy" rating and a $42.00 price objective for the company. Leerink Partners downgraded shares of Spyglass Pharma to a "market perform" rating in a research report on Tuesday. Stifel Nicolaus began coverage on shares of Spyglass Pharma in a report on Tuesday. They issued a "buy" rating and a $42.00 price objective for the company. Finally, Wall Street Zen raised Spyglass Pharma to a "hold" rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat, Spyglass Pharma has an average rating of "Buy" and an average price target of $47.00.View Our Latest Report on Spyglass PharmaSpyglass Pharma Stock Up 0.1%Shares of SGP stock opened at $26.75 on Tuesday. Spyglass Pharma has a 1 year low of $20.16 and a 1 year high of $32.44. Insider ActivityIn other Spyglass Pharma news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of the stock in a transaction dated Monday, February 9th. The shares were bought at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the purchase, the director directly owned 5,966,439 shares of the company's stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Spyglass Pharma Company Profile (Get Free Report)We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).Further ReadingFive stocks we like better than Spyglass PharmaNew Copper-Rich “Kraken” Zone DiscoveredAmerica’s 1776 happening again3 Signs You May Want to Switch Financial AdvisorsSilver's squeeze is tightening - opportunity formingTrump's NEW Executive Order - BIG Changes Coming to Retirement AccountsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Spyglass Pharma Right Now?Before you consider Spyglass Pharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.While Spyglass Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here